Cover Image
市場調查報告書

RAC-伽馬絲胺酸/蘇氨酸蛋白激酶:開發中產品分析

RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365755
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
RAC-伽馬絲胺酸/蘇氨酸蛋白激酶:開發中產品分析 RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 53 Pages
簡介

本報告提供以RAC-伽馬絲胺酸/蘇氨酸蛋白激酶為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

RAC-伽馬絲胺酸/蘇氨酸蛋白激酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • ArQule, Inc.
  • AstraZeneca Plc
  • Cipher Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Novartis AG

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1000TDB

Summary:

RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - RAC-gamma serine/threonine-protein kinase is an enzyme encoded by the AKT3 gene. AKT3 regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. It plays an important role in brain development and viability of malignant glioma cells. It is required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands.

RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase II and Preclinical stages are 6 and 2 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Cervical Cancer, Fallopian Tube Cancer, Melanoma, Metastatic Pancreatic Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor), Colorectal Cancer, Congenital Vascular Malformation, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Lung Cancer, Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Hamartoma Syndrome, Neuroendocrine Cancer, Orphan Diseases, Prostate Cancer, Proteus Syndrome, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sickle Cell Disease and Solid Tumor.

The latest report RAC Gamma SerineThreonine Protein Kinase - Pipeline Review, H2 2017, outlays comprehensive information on the RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1)
  • The report reviews RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Overview
    • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • ArQule Inc
    • AstraZeneca Plc
    • Cipher Pharmaceuticals Inc
    • Merck & Co Inc
    • Novartis AG
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Drug Profiles
    • ARQ-092 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-5363 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISC-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JRP-890 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-2206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-2206 + selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trametinib dimethyl sulfoxide + uprosertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • uprosertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Dormant Products
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
      • May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting
      • Dec 03, 2016: Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
      • Jan 28, 2016: ArQule Provides Update on ARQ 092
      • Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092
      • Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
      • Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics
      • Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology
      • Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference
      • Nov 13, 2014: ArQule Announces Data Presentations on ARQ 092 at 26th EORTC-NCI-AACR Symposium
      • Nov 11, 2014: ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome
      • Oct 21, 2013: New Drug Combinations May Benefit Patients With Pancreatic Cancer
      • Apr 09, 2013: ArQule's New AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase I Trial
      • Apr 07, 2013: AstraZeneca's AKT Inhibitor AZD5363 Well Tolerated, Yieldes Partial Response In Patients With Advanced Solid Tumors, Phase I Study Finds
      • Nov 10, 2011: Daiichi Sankyo To License ARQ 092 From ArQule, The First New Compound Resulting From The Companies' Joint AKIP Research Collaboration
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by ArQule Inc, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by Cipher Pharmaceuticals Inc, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top